UNBELIEVABLE: Axogen - The Untold Story

3 Emerging Biotech Stocks With Significant Upside Potential

Delcath Systems, Viking Therapeutics and AxoGen show growth potential backed by analyst Moderate Buy ratings and strong institutional ownership, despite risks like dilution and patent cliffs.

MarketBeat · Sep 30

AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam

AxoGen (NASDAQ:AXGN) President and CEO Michael Dale said the company’s growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are expected to be positive but have not yet been quantified. Speaking during a company event, Dale said he w

MarketBeat · May 14

AxoGen Stock Rockets 12% on Q1 2026 Revenue Beat, Raised Guidance and Debt-Free Balance Sheet

AxoGen Inc. shares surged more than 11% on Tuesday, April 28, 2026, climbing to $43.98 in morning trading after the peripheral nerve repair company delivered a strong first-quarter revenue beat, posted adjusted profitability and raised its full-year 2026 guidance while announcing it had become debt-free following a successful public offering.

International Business Times · Apr 28

Axogen: Q4 Earnings Insights

Axogen (NASDAQ:AXGN) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Axogen beat estimated earnings by 38.46%, reporting an EPS of $-0.08 versus an estimate of $-0.13.

Benzinga · Feb 22, 2022